Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | PALB2 |
Variant | W1038* |
Impact List | nonsense |
Protein Effect | loss of function |
Gene Variant Descriptions | PALB2 W1038* results in a premature truncation of the Palb2 protein at amino acid 1038 of 1186 (UniProt.org). W1038* confers a loss of function to the Palb2 protein as demonstrated by decreased protein stability (PMID: 31757951), aberrant cytosolic accumulation, decreased Brca2 binding and Rad51 foci formation (PMID: 28158555), and impaired homologous recombination in cultured cells (PMID: 28158555, PMID: 31757951). |
Associated Drug Resistance | |
Category Variants Paths |
PALB2 mutant PALB2 inact mut PALB2 W1038* |
Transcript | NM_024675.4 |
gDNA | chr16:g.23621362C>T |
cDNA | c.3113G>A |
Protein | p.W1038* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017023672.2 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
NM_001407301.1 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
NM_001407299.1 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
NM_024675.3 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
XM_017023672 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
NM_024675.4 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
NM_024675 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
XM_017023673 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
XM_017023673.2 | chr16:g.23621362C>T | c.3113G>A | p.W1038* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 W1038* | Advanced Solid Tumor | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) resulted in decreased survival of TP53-knockout cells expressing PALB2 W1038* in culture (PMID: 31757951). | 31757951 |